Industry News: Medicsight upgrades ColonCAD

Article

The latest version of CT colonography software from Medicsight debuted this week at ECR 2009.

The latest version of CT colonography software from Medicsight debuted this week at ECR 2009. The newly enhanced software, dubbed ColonCAD API 4.0, uses a more powerful algorithm to uncover colorectal polyps in CT data. The CE-Marked product, which will be sold through the company’s European distributors, offers increased specificity that cuts the number of false positive CAD marks per case.

Internal tests involving patient cases demonstrated that the ColonCAD API 4.0 remains as sensitive as the previous version, but displays 50% fewer false positive marks. This works out to a mean of 6.5 false marks per patient case, according to the company. Sensitivity is 85% for polyps 2mm to 50 mm; 90% for polyps 6mm to 9 mm; and 92% for polyps 10mm and larger.
 

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.